M-CSF improves protection against bacterial and fungal infections after hematopoietic stem/progenitor cell transplantation

Journal of Experimental Medicine

Volumn 213, Issue 11, 2016, Pages 2269-2279

  Kandalla, Prashanth K ^a   Sarrazin, Sandrine ^a   Molawi, Kaaweh ^a,d   Berruyer, Carole ^a   Redelberger, David ^c   Favel, Anne ^b   Bordi, Christophe ^c   de Bentzmann, Sophie ^c   Sieweke, Michael H ^a,d  

^a CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

^b CNRS   (France)

^c CNRS and Aix Marseille University   (France)

^d MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; PEGFILGRASTIM; RECOMBINANT COLONY STIMULATING FACTOR 1; TRANSCRIPTION FACTOR PU 1; COLONY STIMULATING FACTOR 1; GLUCOSE BLOOD LEVEL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPERGILLUS FUMIGATUS; BACTERIAL INFECTION; BACTERIAL LOAD; BONE MARROW CELL; CELL DIFFERENTIATION; CELL LINEAGE; CONTROLLED STUDY; DRUG EFFICACY; ENGRAFTMENT; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INFECTION PREVENTION; INFECTION SENSITIVITY; LETHAL DOSE; MOUSE; MYCOSIS; MYELOPOIESIS; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PSEUDOMONAS AERUGINOSA; STEM CELL SELF-RENEWAL; SURVIVAL RATE; THROMBOCYTE COUNT; TREATMENT OUTCOME; ANIMAL; ASPERGILLOSIS; ASPERGILLUS; BLOOD; C57BL MOUSE; CELL SELF-RENEWAL; CYTOLOGY; DRUG EFFECTS; HEMATOPOIETIC STEM CELL; HUMAN; METABOLISM; MICROBIOLOGY; PHYSIOLOGY; PSEUDOMONAS INFECTIONS; THROMBOCYTE;

ANIMALS; ASPERGILLOSIS; ASPERGILLUS; BLOOD GLUCOSE; BLOOD PLATELETS; CELL DIFFERENTIATION; CELL LINEAGE; CELL SELF RENEWAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; MACROPHAGE COLONY-STIMULATING FACTOR; MICE, INBRED C57BL; MYELOPOIESIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84994662221     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20151975     Document Type: Article

References (36)

1. Baldridge, M.T., K.Y. King, and M.A. Goodell. 2011. Inflammatory signals regulate hematopoietic stem cells. Trends Immunol. 32:57-65. http://dx.doi.org/10.1016/j.it.2010.12.003.
2. BitMansour, A., S.M. Burns, D. Traver, K. Akashi, C.H. Contag, I.L. Weissman, and J.M. Brown. 2002. Myeloid progenitors protect against invasive aspergillosis and Pseudomonas aeruginosa infection following hematopoietic stem cell transplantation. Blood. 100:4660-4667. http://dx.doi.org/10.1182/blood-2002-05-1552.
3. BitMansour, A., T.M. Cao, S. Chao, S. Shashidhar, and J.M. Brown. 2005. Single infusion of myeloid progenitors reduces death from Aspergillus fumigatus following chemotherapy-induced neutropenia. Blood. 105:3535-3537. http://dx.doi.org/10.1182/blood-2004-07-2676.
4. Bodine, D.M., N.E. Seidel, and D. Orlic. 1996. Bone marrow collected 14. days after in vivo administration of granulocyte colony-stimulating factor and stem cell factor to mice has 10-fold more repopulating ability than untreated bone marrow. Blood. 88:89-97.
5. Bryder, D., D.J. Rossi, and I.L. Weissman. 2006. Hematopoietic stem cells: the paradigmatic tissue-specific stem cell. Am. J. Pathol. 169:338-346. http://dx.doi.org/10.2353/ajpath.2006.060312.
6. Bukowski, R.M., G.T. Budd, J.A. Gibbons, R.J. Bauer, A. Childs, J. Antal, J. Finke, L. Tuason, V. Lorenzi, D. McLain, et al. 1994. Phase I trial of subcutaneous recombinant macrophage colony-stimulating factor: clinical and immunomodulatory effects. J. Clin. Oncol. 12:97-106.
7. Cheers, C., A.M. Haigh, A. Kelso, D. Metcalf, E.R. Stanley, and A.M. Young. 1988. Production of colony-stimulating factors (CSFs) during infection: separate determinations of macrophage-, granulocyte-, granulocyte-macrophage-, and multi-CSFs. Infect. Immun. 56:247-251.
8. de Haan, G., B. Dontje, C. Engel, M. Loeffler, and W. Nijhof. 1995. The kinetics of murine hematopoietic stem cells in vivo in response to prolonged increased mature blood cell production induced by granulocyte colony-stimulating factor. Blood. 86:2986-2992.
9. Dekker, A., S. Bulley, J. Beyene, L.L. Dupuis, J.J. Doyle, and L. Sung. 2006. Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation. J. Clin. Oncol. 24:5207-5215. http://dx.doi.org/10.1200./JCO.2006.06.1663.
10. De Santa, F., V. Narang, Z.H. Yap, B.K. Tusi, T. Burgold, L. Austenaa, G. Bucci, M. Caganova, S. Notarbartolo, S. Casola, et al. 2009. Jmjd3 contributes to the control of gene expression in LPS-activated macrophages. EMBO J. 28:3341-3352. http://dx.doi.org/10.1038/emboj.2009.271.
11. Garnick, M.B., and J.B. Stoudemire. 1990. Preclinical and clinical evaluation of recombinant human macrophage colony-stimulating factor (rhM-CSF). Int. J. Cell Cloning. 8:356-373. http://dx.doi.org/10.1002/stem.5530080733.
12. Giraud, C., C.S. Bernard, V. Calderon, L. Yang, A. Filloux, S. Molin, G. Fichant, C. Bordi, and S. de Bentzmann. 2011. The PprA-PprB two-component system activates CupE, the first non-archetypal Pseudomonas aeruginosa chaperone-usher pathway system assembling fimbriae. Environ. Microbiol. 13:666-683. http://dx.doi.org/10.1111/j.1462-2920.2010.02372.x
13. Hamilton, J.A., and A. Achuthan. 2013. Colony stimulating factors and myeloid cell biology in health and disease. Trends Immunol. 34:81-89. http://dx.doi.org/10.1016/j.it.2012.08.006.
14. Hashimoto, D., A. Chow, M. Greter, Y. Saenger, W.H. Kwan, M. Leboeuf, F. Ginhoux, J.C. Ochando, Y. Kunisaki, N. van Rooijen, et al. 2011. Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic hematopoietic cell transplantation. J. Exp. Med. 208:1069-1082. http://dx.doi.org/10.1084/jem.20101709.
15. Heuser, M., A. Ganser, C. Bokemeyer. American Society of Clinical Oncology, National Comprehensive Cancer Network, and European Organization for Research and Treatment of Cancer. 2007. Use of colony-stimulating factors for chemotherapy-associated neutropenia: review of current guidelines. Semin. Hematol. 44:148-156. http://dx.doi.org/10.1053/j.seminhematol.2007.04.002.
16. Hume, D.A., and K.P. MacDonald. 2012. Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood. 119:1810-1820. http://dx.doi.org/10.1182/blood-2011-09-379214.
17. Kimura, F., K. Sato, H. Akiyama, H. Sao, S. Okamoto, N. Kobayashi, M. Hara, K. Kawa, and K. Motoyoshi. Japan Marrow Donor Program. 2012. M-CSF attenuates severity of chronic GVHD after unrelated BMT. Bone Marrow Transplant. 47:426-429. http://dx.doi.org/10.1038/bmt.2011.90.
18. King, K.Y., and M.A. Goodell. 2011. Inflammatory modulation of HSCs: viewing the HSC as a foundation for the immune response. Nat. Rev. Immunol. 11:685-692. http://dx.doi.org/10.1038/nri3062.
19. Koch, B., L.E. Jensen, and O. Nybroe. 2001. A panel of Tn7-based vectors for insertion of the gfp marker gene or for delivery of cloned DNA into Gram-negative bacteria at a neutral chromosomal site. J. Microbiol. Methods. 45:187-195. http://dx.doi.org/10.1016/S0167-7012(01)00246-9.
20. Latgé, J.P. 1999. Aspergillus fumigatus and aspergillosis. Clin. Microbiol. Rev. 12:310-350.
21. Manz, M.G., and S. Boettcher. 2014. Emergency granulopoiesis. Nat. Rev. Immunol. 14:302-314. http://dx.doi.org/10.1038/nri3660.
22. Metcalf, D. 2008. Hematopoietic cytokines. Blood. 111:485-491. http://dx.doi.org/10.1182/blood-2007-03-079681.
23. Mirantes, C., E. Passegué, and E.M. Pietras. 2014. Pro-inflammatory cytokines: emerging players regulating HSC function in normal and diseased hematopoiesis. Exp. Cell Res. 329:248-254. http://dx.doi.org/10.1016/j.yexcr.2014.08.017.
24. Mossadegh-Keller, N., S. Sarrazin, P.K. Kandalla, L. Espinosa, E.R. Stanley, S.L. Nutt, J. Moore, and M.H. Sieweke. 2013. M-CSF instructs myeloid lineage fate in single haematopoietic stem cells. Nature. 497:239-243. http://dx.doi.org/10.1038/nature12026.
25. Munn, D.H., M.B. Garnick, and N.K. Cheung. 1990. Effects of parenteral recombinant human macrophage colony-stimulating factor on monocyte number, phenotype, and antitumor cytotoxicity in nonhuman primates. Blood. 75:2042-2048.
26. Nemunaitis, J., K. Shannon-Dorcy, F.R. Appelbaum, J. Meyers, A. Owens, R. Day, D. Ando, C. O'Neill, D. Buckner, and J. Singer. 1993. Long-term follow-up of patients with invasive fungal disease who received adjunctive therapy with recombinant human macrophage colony-stimulating factor. Blood. 82:1422-1427.
27. Pixley, F.J., and E.R. Stanley. 2004. CSF-1 regulation of the wandering macrophage: complexity in action. Trends Cell Biol. 14:628-638. http://dx.doi.org/10.1016/j.tcb.2004.09.016.
28. Sarrazin, S., and M. Sieweke. 2011. Integration of cytokine and transcription factor signals in hematopoietic stem cell commitment. Semin. Immunol. 23:326-334. http://dx.doi.org/10.1016/j.smim.2011.08.011.
29. Sarrazin, S., N. Mossadegh-Keller, T. Fukao, A. Aziz, F. Mourcin, L. Vanhille, L. Kelly Modis, P. Kastner, S. Chan, E. Duprez, et al. 2009. MafB restricts M-CSF-dependent myeloid commitment divisions of hematopoietic stem cells. Cell. 138:300-313. http://dx.doi.org/10.1016/j.cell.2009.04.057.
30. Schuettpelz, L.G., J.N. Borgerding, M.J. Christopher, P.K. Gopalan, M.P. Romine, A.C. Herman, J.R. Woloszynek, A.M. Greenbaum, and D.C. Link. 2014. G-CSF regulates hematopoietic stem cell activity, in part, through activation of Toll-like receptor signaling. Leukemia. 28:1851-1860. http://dx.doi.org/10.1038/leu.2014.68.
31. Sung, L., P.C. Nathan, S.M. Alibhai, G.A. Tomlinson, and J. Beyene. 2007. Metaanalysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann. Intern. Med. 147:400-411. http://dx.doi.org/10.7326/0003-4819-147-6-200709180-00010.
32. To, L.B., D.N. Haylock, P.J. Simmons, and C.A. Juttner. 1997. The biology and clinical uses of blood stem cells. Blood. 89:2233-2258.
33. Tomblyn, M., T. Chiller, H. Einsele, R. Gress, K. Sepkowitz, J. Storek, J.R. Wingard, J.A. Young, M.J. Boeckh. Center for International Blood and Marrow Research and Centers for Disease Control and Prevention. 2009. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol. Blood Marrow Transplant. 15:1143-1238. http://dx.doi.org/10.1016/j.bbmt.2009.06.019.
34. Wan, L., Y. Zhang, Y. Lai, M. Jiang, Y. Song, J. Zhou, Z. Zhang, X. Duan, Y. Fu, L. Liao, and C. Wang. 2015. Effect of granulocyte-macrophage colony-stimulating factor on prevention and treatment of invasive fungal disease in recipients of allogeneic stem-cell transplantation: A prospective multicenter randomized phase IV trial. J. Clin. Oncol. 33:3999-4006. http://dx.doi.org/10.1200/JCO.2014.60.5121.
35. Winkler, I.G., A.R. Pettit, L.J. Raggatt, R.N. Jacobsen, C.E. Forristal, V. Barbier, B. Nowlan, A. Cisterne, L.J. Bendall, N.A. Sims, and J.P. Lévesque. 2012. Hematopoietic stem cell mobilizing agents G-CSF, cyclophosphamide or AMD3100 have distinct mechanisms of action on bone marrow HSC niches and bone formation. Leukemia. 26:1594-1601. http://dx.doi.org/10.1038/leu.2012.17.
36. Zhao, J.L., and D. Baltimore. 2015. Regulation of stress-induced hematopoiesis. Curr. Opin. Hematol. 22:286-292.